The largest database of trusted experimental protocols

Phoenix 7

Manufactured by Certara
Sourced in United States

Phoenix® 7.0 is a software application designed for pharmacometric analysis and modeling. It provides a comprehensive platform for performing nonlinear mixed-effects modeling, population pharmacokinetic and pharmacodynamic analyses, and model-based clinical trial simulations.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using phoenix 7

1

Hesperetin-Spiked Plasma Bioanalysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma samples were thawed on ice. Blank mouse plasma was used for standard curves. Plasma aliquots (100 ul) were spiked with hesperetin (10 ul, 5000 ng/ml) as an internal standard and mixed by vortexing. Drugs were extracted with simple protein precipitation using cold acetonitrile, and the mixture was centrifuged at 13000 × g for 10 min. The supernatant was collected and dried under nitrogen. Dried samples were reconstituted with 200 ul 1% formic acid. Samples were analyzed using liquid chromatography–tandem mass spectrometry (LC-MS/MS) system consisting of Thermo Accela UHPLC pump, Thermo PAL autosampler, and Thermo TSQ Discovery triple quadruple mass spectrometer (Thermo, Waltham, MA, USA). Chromatographic separation was done using an Agilent Zobrax Extend C-18 column. Linear gradient elution was used at a flow rate of 400 ul/min, with a mobile phase of 0.5% acetonitrile and 95% acetonitrile, modified with 0.2% formic acid. Non-compartmental analysis of the pharmacokinetic parameters as well as compartmental model fitting of the data was carried using Phoenix® 7.0 (Certara, New Jersey, USA).
+ Open protocol
+ Expand
2

Phase I Study of RO4929097 and Paclitaxel

Check if the same lab product or an alternative is used in the 5 most similar protocols
Summary statistics were calculated for patient and clinical characteristics. Toxicities were also summarized by grade per the NCI CTCAE v4.0 criteria using frequency and percentage. Patients who received at least one dose of RO4929097 were evaluable for toxicity. Clinico-pathological response was also summarized using frequency table for all patients and the change of tumor measures from baseline for each patient was explored longitudinally using spider plots. These analyses were conducted in SAS version 9.04 (SAS Institute, Cary, North Carolina). Non-compartmental analyses of the PK parameters for both RO9429097 and paclitaxel were carried out using Phoenix® 7.0 (Certara, New Jersey, USA). Differences in plasma exposure were evaluated using area under the curve (AUC) and compared using student t-tests. Statistical significance was concluded at p value ≤0.05.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!